Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Acquired by Cutter Capital Management LP

Cutter Capital Management LP raised its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 23.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 212,696 shares of the company's stock after buying an additional 39,820 shares during the period. Vera Therapeutics comprises about 3.7% of Cutter Capital Management LP's investment portfolio, making the stock its 13th biggest position. Cutter Capital Management LP owned 0.34% of Vera Therapeutics worth $8,995,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of VERA. Huntington National Bank bought a new position in Vera Therapeutics in the 4th quarter worth $26,000. AlphaQuest LLC bought a new stake in shares of Vera Therapeutics during the fourth quarter valued at approximately $34,000. KBC Group NV boosted its position in shares of Vera Therapeutics by 127.2% during the fourth quarter. KBC Group NV now owns 2,477 shares of the company's stock valued at $105,000 after buying an additional 1,387 shares during the last quarter. Summit Investment Advisors Inc. grew its stake in shares of Vera Therapeutics by 16.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock worth $196,000 after acquiring an additional 639 shares during the period. Finally, Moors & Cabot Inc. purchased a new position in shares of Vera Therapeutics in the 4th quarter worth $220,000. Hedge funds and other institutional investors own 99.21% of the company's stock.

Analysts Set New Price Targets

Several analysts recently issued reports on VERA shares. JPMorgan Chase & Co. cut their target price on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research report on Tuesday, March 4th. Wolfe Research initiated coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price objective on the stock. Cantor Fitzgerald reduced their target price on shares of Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating for the company in a report on Wednesday. HC Wainwright began coverage on shares of Vera Therapeutics in a report on Monday, May 5th. They set a "buy" rating and a $75.00 price target on the stock. Finally, Wedbush lowered their target price on shares of Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Vera Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $63.33.

Vera Therapeutics Price Performance

Shares of NASDAQ:VERA traded down $0.26 during mid-day trading on Friday, reaching $21.77. The stock had a trading volume of 1,262,456 shares, compared to its average volume of 778,875. The business's 50 day moving average price is $24.22 and its 200 day moving average price is $34.68. Vera Therapeutics, Inc. has a 1 year low of $18.53 and a 1 year high of $51.61. The company has a market cap of $1.39 billion, a P/E ratio of -8.34 and a beta of 1.28. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same quarter in the previous year, the firm earned ($0.56) EPS. Research analysts expect that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.